

Development of a Rapid Point-of-Care Diagnostic Kit for Differentiating CSF rhinorrhea from Benign Nasal Discharge

Young Il Kim, PhD¹, Yeon Hee Im, PhD², Kyuha Chong, PhD³, Rowoon Park, PhD⁴, Ho Sang Jung PhD⁴, Seung Ho Yang, PhD¹

¹Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
²Department of Otorhinolaryngology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
³Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
⁴School of Biomedical Engineering, College of Health Science, Korea University

Background

Accurate differentiation between cerebrospinal fluid (CSF) and benign nasal secretions is a clinically important yet persistent challenge in multiple settings, including postoperative care after endoscopic endonasal skull base surgery and evaluation after traumatic skull base injury. Current diagnostic approaches—most commonly laboratory-based β 2-transferrin assays and adjunctive tests such as glucose concentration analysis—are used in practice to support confirmation of CSF. However, these methods are limited by cost, delayed turnaround times, and variable diagnostic performance across different sample conditions and clinical contexts. As a result, timely decision-making may be hindered when rapid confirmation is needed.

Objective

This study aims to develop a **rapid point-of-care (POC) diagnostic kit** that can reliably identify CSF in nasal discharge. The project will (1) **screen and prioritize clinically relevant biomarker candidates** and (2) **evaluate their suitability for integration into a practical detection platform** designed for use across high-need clinical pathways. This early-stage effort is built on a multidisciplinary collaboration among **neurosurgery, otolaryngology (ENT), and materials science**, aligning real-world clinical requirements with biosensor/platform feasibility from the outset.

Methods and Materials

Materials characterization for the UGN substrate




Figure 1. Materials characterization for the UGN substrate. (a) Schematic diagram of the plasmonic sensing platform for CSF rhinorrhea diagnostics. (b) The formation mechanism of the UGN. (c) Photograph of the synthesized UGN substrate. (d) SEM image of the UGN. (e) The particle and protrusion size distribution of the UGN, (f) XRD spectrum showing polycrystalline structure. (g) FDTD simulation to find E-field distribution.

Contact

Young Il Kim, PhD
Department of Neurosurgery, St. Vincent's Hospital, College of Medicine,
The Catholic University of Korea
93, Jungbu-daero, Paldal-gu, Suwon-si, Gyeonggi-do, 16247, Republic of Korea
medi0204@gmail.com
+82-10-8998-2486

Results

Plasmonic properties and SERS performance of the UGN sensor




Figure 2. Plasmonic properties and SERS performance of the UGN sensor. (a) SERS performance and (b) standard curve of the UGN sensor at various MG concentrations under 785 nm excitations. (c) signal uniformity test at 400 different points. (d) reproducibility test with ten different UGN substrates.

Relative quantification of CSF proteins using combined NNLS analysis.




Figure 3. Machine learning-based classification and mathematical modeling for biomarker quantification. (a) SERS spectra of individual biomarkers: β 1-transferrin (β 1-TF), β 2-transferrin (β 2-TF), Osteopontin (OPN), and Tau protein. (b) ROC curve and confusion matrix showing the classification performance between β 1-TF and β 2-TF proteins. (c) Schematic diagram of the Non-negative Least Squares (NNLS)-based mathematical modeling for signal deconvolution. (d) Comparison of NNLS-derived relative contributions of β 2-TF, OPN, and Tau proteins for four representative patients.

Conclusions

This early-stage, multidisciplinary project addresses a well-recognized clinical gap in the diagnosis of CSF rhinorrhea. By integrating clinical insight from neurosurgery and otolaryngology with materials science-based diagnostic development, this study aims to lay the groundwork for a rapid, practical POC diagnostic kit. Further biomarker validation and clinical testing will be essential steps toward improving clinical decision making and patient safety in skull base surgery and CSF leak management.

References

- Oakley GM, Alt JA, Schlosser RJ, Harvey RJ, Orlandi RR. **Diagnosis of cerebrospinal fluid rhinorrhea: An evidence-based review with recommendations.** *Int Forum Allergy Rhinol.* 2016;6(1):8–16. doi:10.1002/ia.21637.
- Torabi SJ, Abiri A, Chen X, Senel M, Hsu FPK, Luptak A, et al. **Multimodal diagnosis of cerebrospinal fluid rhinorrhea: State-of-the-art review and emerging concepts.** *Laryngoscope Invest Otolaryngol.* 2024;9(3):e1272. doi:10.1002/lio2.1272.
- Bhat SN, Thunga G, Kamath A, Chandrababu R, Shetty P, Kalthur G, et al. **CSF biomarkers in leak detection: A systematic review and meta-analysis of diagnostic test accuracy studies.** *Clin Chim Acta.* 2025;577:120458. doi:10.1016/j.cca.2025.120458.
- Eide JG, Mason W, Mackie H, Cook B, Ray A, Asmaro K, et al. **Diagnostic Accuracy of Beta-2 Transferrin Gel Electrophoresis for Detecting Cerebrospinal Fluid Rhinorrhea.** *Laryngoscope.* 2025;135(1):94–96. doi:10.1002/lary.31845.
- Chou YH, Huang YH, et al. **High-sensitivity lateral flow immunoassay (stacking pad) for β -trace protein detection in CSF leak screening.** *Anal Biochem.* 2022;654:114796. doi:10.1016/j.ab.2022.114796.